" class="no-js "lang="en-US"> Coeptis Therapeutics - Medtech Alert
Sunday, June 16, 2024
Coeptis Therapeutics | MTA

Coeptis Therapeutics

About Coeptis Therapeutics

Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.

Related Story

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

May 17 2023

Coeptis Therapeutics, a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the […]

Coeptis Therapeutics Secures Exclusive Rights to Negotiate the Acquisition of Transformational Cell Therapy Platform

March 29 2023

Coeptis Therapeutics, a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has […]